查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995405

藥用明膠市場：按類型、形態、原料、應用和分銷管道分類－2026-2032年全球市場預測

Pharmaceutical Gelatin Market by Type, Form, Raw Material, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥用明膠市場價值將達到 13 億美元，到 2026 年將成長到 13.8 億美元，到 2032 年將達到 19.8 億美元，複合年成長率為 6.18%。

主要市場統計數據
基準年 2025 13億美元
預計年份：2026年 13.8億美元
預測年份 2032 19.8億美元
複合年成長率 (%) 6.18%

全面概述影響配方和採購決策的藥用明膠的基本原理、監管要求和供應考慮因素。

医薬用ゼラチンは、製剤、カプセル化、コーティング用途において極めて重要な役割を果たしており、素材の品質は製品の安定性や患者の治療成果に直接影響を与えます。本執行摘要の導入では、ゼラチンの機能的特性（生体適合性、皮膜形成能力、および制御された溶解挙動）を說明するとともに、剤形開発のライフサイクル全体におけるゼラチンの位置づけを明らかにします。規制当局の監視、サプライチェーンの継続性、および原料のトレーサビリティは、調達および製剤のリスクプロファイルを決定づける中心的なテーマです。

永續性、先進分析和不斷提高的品質期望如何改變明膠的採購、製造實踐和供應商夥伴關係。

医薬品用ゼラチンの業界では、籌資策略や製品開発の道筋を再構築する収束的な変化が起きています。サステナビリティや動物福祉への関心の高まりにより、原料の産地や製作流程に対する監視が強化され、メーカーはトレーサビリティ体制の拡充や代替供給源の模索を迫られています。一方、分析化学やプロセスバリデーションの進歩により、品管の基準が引き上げられ、ロット間の残留溶媒、微生物限度、機能性能について、より詳細な試験が求められるようになっています。

評估累積關稅對影響明膠採購、庫存策略、配方開發時間表和供應商多元化的韌性措施的影響。

近年の関税賦課や貿易政策の転換は、世界のサプライチェーンで事業を展開するゼラチン購入者や製造業者にとって、調達計画やコスト構造に新たな動きをもたらしました。多重の関税は、着荷コストだけでなく、サプライヤーの選定、在庫戦略、そして原料調達先の地理的分散にも影響を及ぼします。これに対応し、調達チームは関税変動によるリスクを軽減するため、垂直統合の選択肢や在地採購を再評価しています。

綜合細分分析揭示了採購來源、類型、形式、用途和通路的選擇如何全面決定明膠的性能和供應風險狀況。

素材の選定、加工方法、流通チャネルの動向に焦点を当てた複数の分析的觀點を通じて市場を檢驗することで、市場セグメンテーションに関する洞察が得られます。牛、魚、豚の各原産地による原料の差異を検討する際、それぞれの選択肢には、製品設計の決定や市場での受容性を左右する、特有の官能的、文化的、規制上の考慮事項が存在します。原料の選定は、多くの場合、最終市場の感性、地域の食習慣上の制約、および剤形に求められる特定の機能的特性によって左右されます。

將區域趨勢進行比較，解釋美洲、歐洲、中東和非洲以及亞太地區的差異如何影響採購、合規和打入市場策略。

地域ごとの動向は、調達オプション、法律規範、および最終市場の需要パターンに顕著な影響を及ぼします。アメリカ大陸では、購買戦略は、確立された製造群、トレーサビリティに対する規制上の期待、およびカプセルやコーティング用の幅広いゼラチングレードを支える成熟した供給基盤によって形作られることがよくあります。この地域の生産および流通ネットワークは、タイムリーな物流と規制順守を優先しており、これがサプライヤーの合格性評価通訊協定や在庫配置の指南となっています。

透過可追溯性、分析能力、共享品質協議和增值技術服務來強調供應商差異化的競爭優勢。

ゼラチン分野における競爭考察は、価格のみではなく、トレーサビリティ、品質保証、および技術サービスにおけるサプライヤーの能力に焦点を当てています。主要サプライヤーは、上游工程のトレーサビリティシステム、高度な分析研究所、およびカプセルメーカーやコーティング製剤メーカー向けのカスタマイズされた製品開発支援への投資を通じて差別化を図っています。これらの能力により、サプライヤーは、顧客固有の規制関連資料に対応しつつ、厳格な溶解性および安定性要件を満たす仕様を共同で策定することが可能になります。

供應商和製造商可採取的策略重點，以增強可追溯性、實現採購多元化、提高分析保證和擴大增值技術服務。

業界の領導企業は、供給の確実性、製品の性能、および規制への適合性を高める戦略的取り組みを優先すべきです。原料の産地から完成品に至るまでの包括的なトレーサビリティシステムへの投資は、コンプライアンスリスクを低減し、商業性的関係を強化することになります。同様に重要なのは、機能性能試験をサポートする高度な分析プラットフォームの導入であり、これにより製造バッチ間でのカプセルおよびコーティングの挙動の一貫性を高めることが可能になります。

採用透明的混合方法研究設計，結合相關人員訪談、技術文獻整合、貿易流量分析和專家檢驗，確保獲得可靠的策略見解。

本執行摘要の基礎となる調查方法は、一次調査と二次檢驗を融合させ、堅牢かつ実用的な知見を確保するものです。一次調査の主な入力情報には、製造およびサプライヤー組織全体の調達責任者、製剤開発者、品質保証負責人に対する構造化インタビューが含まれます。これらの対話を通じて、調達決定の基準、品質への期待、および貿易措置や規制変更への業務上の適応に関する背景情報が得られます。

綜合結論強調，需要將明膠的選擇視為一項跨部門的策略決策，該決策應基於產地、分析數據和供應彈性。

この結論は、本執行摘要の中心的なテーマを統合したものです。すなわち、ゼラチンの素材特性と産地は、製剤の成功、規制順守、市場での受容性を決定づける要因として、ますます重要性を増しています。利害相關人員は、サステナビリティへの期待、厳格化された分析基準、貿易関連のコスト変動といった、相互に作用するプレッシャーに対処しなければなりません。これらは総合的に、調達およびイノベーションの選択肢を形作っています。したがって、レジリエンスは、調達先の多様化、堅牢なトレーサビリティ、そしてサプライヤーと製造業者間の付加価値のある技術的連携を通じて構築されるのです。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥用明膠市場：按類型分類

  • A型
  • B型

第9章：藥用明膠市場：依形態分類

  • 粉末
  • 座位

第10章：藥用明膠市場：依原料分類

  • 皮革
  • 骨
  • 皮與骨的混合物

第11章 藥用明膠市場：依應用領域分類

  • 硬膠囊
  • 顆粒
  • 軟膠囊
  • 藥片包衣

第12章 藥用明膠市場：依分銷管道分類

  • 離線
  • 線上

第13章 藥用明膠市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥用明膠市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥用明膠市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥用明膠市場

第17章：中國藥用明膠市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Danish Crown Protein A/S
  • Darling Ingredients Inc.
  • Gelco International
  • Gelita AG
  • Italgelatin SpA
  • Lonza Group AG
  • MV Protein Inc.
  • Nippi Inc.
  • Nitta Gelatin Inc.
  • Norland Products Inc.
  • PB Leiner NV
  • Tessenderlo Group NV
  • Weishardt International SAS
Product Code: MRR-4F4C36263656

The Pharmaceutical Gelatin Market was valued at USD 1.30 billion in 2025 and is projected to grow to USD 1.38 billion in 2026, with a CAGR of 6.18%, reaching USD 1.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.30 billion
Estimated Year [2026] USD 1.38 billion
Forecast Year [2032] USD 1.98 billion
CAGR (%) 6.18%

Comprehensive contextual orientation to pharmaceutical gelatin fundamentals, regulatory expectations, and supply considerations that drive formulation and sourcing decisions

Pharmaceutical gelatin occupies a pivotal role across formulation, encapsulation, and coating applications, where material integrity directly influences product stability and patient outcomes. The introduction to this executive summary establishes the material's functional attributes-biocompatibility, film-forming capability, and controlled dissolution behavior-while situating gelatin within the broader lifecycle of dosage-form development. Regulatory scrutiny, supply chain continuity, and raw material traceability are central themes that determine procurement and formulation risk profiles.

As the industry shifts toward patient-centric dosage forms and sustainable sourcing, gelatin suppliers and pharmaceutical manufacturers must reconcile performance demands with ethical and regulatory expectations. Emerging quality frameworks emphasize documentation from source to finished product, requiring closer collaboration between capsule makers, active pharmaceutical ingredient formulators, and analytical labs. Consequently, strategic decisions about source selection, processing parameters, and supplier qualification now factor prominently into commercial development plans.

Taken together, the introduction frames gelatin not merely as an inert excipient but as a material whose provenance, form, and processing influence regulatory outcomes, manufacturing efficiency, and therapeutic performance. The subsequent sections delve into transformative shifts, tariff impacts, segmentation insights, regional dynamics, competitive positioning, actionable recommendations, methodology, and concluding reflections that support commercially defensible decision-making.

How sustainability, advanced analytics, and heightened quality expectations are collectively reshaping gelatin sourcing, manufacturing practices, and supplier partnerships

The landscape for pharmaceutical gelatin is experiencing convergent changes that are reshaping sourcing strategies and product development pathways. Rising emphasis on sustainability and animal welfare has intensified scrutiny on raw material origin and processing, prompting manufacturers to expand traceability mechanisms and seek alternative sources. Meanwhile, advances in analytical chemistry and process validation have raised the bar for quality control, requiring more granular testing for residual solvents, microbial limits, and functional performance across lots.

Concurrently, digital supply chain technologies and near-real-time analytics are enabling tighter inventory control and better visibility into upstream raw material flows. These capabilities reduce batch-to-batch variability and support just-in-time manufacturing without sacrificing compliance. Additionally, customer preferences toward clean-label and ethically sourced ingredients influence procurement policies, driving premium positioning for suppliers who can certify responsible sourcing.

Taken together, these shifts are transforming commercial relationships: purchasers increasingly demand long-term partnerships founded on shared quality systems and transparency. As a result, companies that proactively invest in traceability, environmental stewardship, and robust testing protocols are better positioned to capture formulators seeking reliable gelatin supplies for modern pharmaceutical applications.

Assessment of cumulative tariff effects on gelatin procurement, inventory strategies, and resilience measures that influence formulation timelines and supplier diversification

The imposition of tariffs and trade policy shifts in recent years has introduced new dynamics to procurement planning and cost structures for gelatin buyers and manufacturers operating in global supply chains. Tariff layers affect not only landed cost but also supplier selection, inventory strategy, and the geographic diversification of raw material sources. In response, procurement teams have re-evaluated vertical integration options and local sourcing to mitigate exposure to customs volatility.

Tariff-driven cost pressures have encouraged companies to pursue more rigorous supplier audits and to negotiate longer-term contracts that lock in supply terms and stability. At the same time, organizations have adopted hedging strategies across multiple sourcing regions to preserve continuity of supply when trade measures disrupt conventional shipping lanes. These adjustments are complemented by operational adaptations such as increased safety stock at strategically located manufacturing sites and closer alignment between commercial planning and logistics teams.

Importantly, the cumulative impact of tariffs extends beyond per-unit cost; it influences innovation timelines and market entry strategies. Firms evaluating new capsule formats or coating technologies now incorporate tariff scenarios into feasibility assessments and go-to-market projections. Overall, trade measures have catalyzed more resilient supply chain design, emphasizing flexibility, multi-sourcing, and contractual mechanisms that balance cost management with uninterrupted access to quality gelatin.

Integrated segmentation analysis revealing how source, type, form, application, and distribution choices collectively determine gelatin performance and supply risk profiles

Segmentation insight emerges when the market is examined through multiple analytical lenses that highlight material selection, processing choices, and channel dynamics. When considering source differentiation across bovine, fish, and porcine origins, each option presents distinctive sensory, cultural, and regulatory considerations that shape formulation decisions and market acceptability. Source selection is often driven by end-market sensitivities, regional dietary constraints, and the specific functional attributes required by the dosage form.

Evaluating the material by type-Type A versus Type B-reveals differences in gel strength and isoelectric properties that influence hydration, gelling behavior, and interaction with active ingredients. These type-driven characteristics guide technologists when optimizing capsule hardness, dissolution profiles, and compatibility with encapsulated actives. Form factor distinctions between powder and sheet formats affect manufacturing throughput, handling, and dissolution kinetics; powder forms lend themselves to flexible dosing and rapid blending, whereas sheets support continuous encapsulation lines and can influence film uniformity.

Application-based segmentation-encompassing hard capsule, pellets, soft capsule, and tablet coating-demonstrates how functional requirements vary across dosage forms, requiring tailored gelatin grades, plasticizer systems, and processing conditions. Distribution channels-direct procurement, distributor-mediated supply, and online sourcing-create different risk exposures and service expectations, with direct relationships favoring customized technical support and online channels offering procurement speed and price transparency. By integrating these segmentation dimensions, stakeholders can align product specifications and supply strategies with formulation goals and market access requirements.

Comparative regional dynamics explaining how Americas, Europe, Middle East & Africa, and Asia-Pacific variations drive sourcing, compliance, and market access strategies

Regional dynamics exert a pronounced influence on sourcing options, regulatory frameworks, and end-market demand patterns. In the Americas, purchasing strategies are often shaped by established manufacturing clusters, regulatory expectations for traceability, and a mature supply base that supports a range of gelatin grades for capsules and coatings. Production and distribution networks in this region prioritize timely logistics and regulatory compliance, which informs supplier qualification protocols and inventory positioning.

Europe, Middle East & Africa present a complex mosaic of regulatory regimes, cultural dietary requirements, and demand heterogeneity. Manufacturers in this region weigh halal, kosher, and other certification needs alongside environmental considerations, which affects source selection and supplier auditing practices. The region's regulatory scrutiny emphasizes documentation and adherence to sanitary standards, thereby elevating the importance of supplier transparency and provenance controls.

Asia-Pacific remains a dynamic region with expanding pharmaceutical manufacturing capacity, diverse raw material endowments, and evolving quality norms. Rapid growth in contract manufacturing and generic production has increased demand for reliable gelatin supplies, while local sourcing strategies seek to balance cost competitiveness with international compliance expectations. Across regions, cross-border logistics, certification requirements, and cultural preferences continue to shape where and how gelatin is sourced and deployed.

Competitive profile emphasizing supplier differentiation through traceability, analytical capabilities, collaborative quality agreements, and value-added technical services

Competitive insight in the gelatin arena centers on supplier capabilities in traceability, quality assurance, and technical service rather than solely on price. Leading suppliers differentiate through investments in upstream traceability systems, advanced analytical laboratories, and customized product development support for capsule manufacturers and coating formulators. These capabilities enable suppliers to co-develop specifications that meet stringent dissolution and stability requirements while addressing client-specific regulatory dossiers.

Partnership models have evolved to include collaborative quality agreements, joint risk assessments, and multi-year supply commitments that provide security for both downstream manufacturers and upstream producers. Companies that maintain diversified raw material procurement strategies and multi-modal logistics options are more resilient in the face of disruption. Additionally, organizations that provide transparent documentation, such as chain-of-custody certificates and third-party audit reports, gain preferential consideration among quality-driven buyers.

From a commercialization perspective, suppliers that offer formulation advisory services, rapid-response stability testing, and tailored packaging options command higher strategic value. These services reduce time-to-market for new dosage forms and support rapid scale-up, thereby strengthening customer retention and enabling premium positioning in a market where regulatory compliance and product performance are paramount.

Actionable strategic priorities for suppliers and manufacturers to strengthen traceability, diversify sourcing, enhance analytical assurance, and expand value-added technical services

Industry leaders should prioritize strategic initiatives that enhance supply assurance, product performance, and regulatory alignment. Investing in comprehensive traceability systems from raw material origin through finished product will reduce compliance risk and strengthen commercial relationships. Equally important is the adoption of advanced analytical platforms that support functional performance testing, enabling more consistent capsule and coating behavior across production batches.

Operationally, establishing multi-sourcing strategies and geographically diversified inventories can reduce exposure to trade policy shifts and logistics disruptions. Leaders should formalize supplier partnerships through performance-based contracts and mutual contingency planning, which fosters supply stability and shared accountability. On the commercial front, positioning gelatin offerings with documented sustainability attributes and certification credentials addresses buyer preferences and opens access to markets with dietary or ethical constraints.

Finally, companies should expand value propositions by bundling technical support, stability testing, and rapid-response troubleshooting to accelerate customer product development cycles. By aligning technical services with strategic sourcing and robust quality systems, industry leaders will strengthen market positioning and enable customers to deliver safer, more reliable dosage forms to patients.

Transparent mixed-method research design combining stakeholder interviews, technical literature synthesis, trade flow analysis, and expert validation to ensure reliable strategic insights

The research methodology underpinning this executive summary blends primary engagement and secondary validation to ensure robust, actionable insights. Primary inputs include structured interviews with procurement leaders, formulation scientists, and quality assurance professionals across manufacturing and supplier organizations. These dialogues provide context on sourcing decision criteria, quality expectations, and operational adaptations to trade measures and regulatory changes.

Secondary analysis synthesizes peer-reviewed literature, regulatory guidance documents, and publicly available technical specifications to validate functional assumptions about gelatin types, forms, and application-specific requirements. Trade flow and logistics data inform considerations about cross-border sourcing and inventory strategies, while case studies illustrate practical responses to supply disruptions and certification demands. Triangulation across these sources ensures that conclusions reflect both practitioner experience and documented standards.

Throughout the methodology, emphasis is placed on transparency of assumptions, reproducibility of analytical approaches, and the use of multiple corroborating data points to support each thematic insight. Quality controls include cross-validation of interview findings, review of technical specifications by subject-matter experts, and iterative refinement of conclusions to reflect stakeholder feedback.

Consolidated conclusion highlighting the need to treat gelatin selection as a cross-functional strategic decision driven by provenance, analytics, and supply resilience

The conclusion synthesizes the executive summary's central themes: gelatin's material attributes and provenance are increasingly determinative of formulation success, regulatory compliance, and market acceptance. Stakeholders must navigate converging pressures from sustainability expectations, heightened analytical standards, and trade-related cost fluctuations, which collectively shape procurement and innovation choices. Resilience is therefore built through diversified sourcing, robust traceability, and value-added technical collaboration between suppliers and manufacturers.

Forward-looking organizations will treat gelatin selection as a cross-functional decision involving procurement, R&D, quality, and regulatory affairs rather than a commoditized purchasing choice. By integrating technical support, sustainability credentials, and formalized supplier risk management into procurement frameworks, manufacturers can better assure product performance and regulatory readiness. In sum, the path to competitive advantage lies in aligning material science rigor with supply chain resilience and customer-centric service offerings that accelerate development timelines and support compliant commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Gelatin Market, by Type

  • 8.1. Type A
  • 8.2. Type B

9. Pharmaceutical Gelatin Market, by Form

  • 9.1. Powder
  • 9.2. Sheet

10. Pharmaceutical Gelatin Market, by Raw Material

  • 10.1. Skin
  • 10.2. Bone
  • 10.3. Combined Skin And Bone

11. Pharmaceutical Gelatin Market, by Application

  • 11.1. Hard Capsule
  • 11.2. Pellets
  • 11.3. Soft Capsule
  • 11.4. Tablet Coating

12. Pharmaceutical Gelatin Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Pharmaceutical Gelatin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pharmaceutical Gelatin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pharmaceutical Gelatin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pharmaceutical Gelatin Market

17. China Pharmaceutical Gelatin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Danish Crown Protein A/S
  • 18.6. Darling Ingredients Inc.
  • 18.7. Gelco International
  • 18.8. Gelita AG
  • 18.9. Italgelatin SpA
  • 18.10. Lonza Group AG
  • 18.11. MV Protein Inc.
  • 18.12. Nippi Inc.
  • 18.13. Nitta Gelatin Inc.
  • 18.14. Norland Products Inc.
  • 18.15. PB Leiner NV
  • 18.16. Tessenderlo Group NV
  • 18.17. Weishardt International SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACEUTICAL GELATIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SHEET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SHEET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SHEET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SKIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SKIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SKIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY BONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY BONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY BONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COMBINED SKIN AND BONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COMBINED SKIN AND BONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COMBINED SKIN AND BONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY HARD CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY HARD CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY HARD CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SOFT CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SOFT CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SOFT CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TABLET COATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TABLET COATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TABLET COATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)